Skip to main content
Clinical Trials/ISRCTN89404187
ISRCTN89404187
Completed
Phase 4

A prospective, multi-center, post-market surveillance study to assess the clinical efficacy and fusion rates of the Zimmer®TM Ardis Interbody Fusion System

Zimmer Spine (France)0 sites80 target enrollmentJanuary 27, 2014

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Zimmer Spine (France)
Enrollment
80
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 27, 2014
End Date
May 31, 2018
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Zimmer Spine (France)

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 18 years or over
  • 2\. Degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies.
  • 3\. ODI over or equal to 40/100
  • 4\. Back pain over or equal to 4/10
  • 5\. Mono segmental lumbosacral disease fulfilling the prior conditions: only one level between L2 and S1
  • 6\. Skeletally mature patients
  • 7\. Six months failed conservative treatment
  • 8\. Gave written consent to take part in the study by signing patient informed consent form
  • 9\. Physically and mentally able to comply with the protocol, including ability to read and complete required forms and adhere to the follow\-up requirements of the protocol

Exclusion Criteria

  • 1\. Prior surgical procedure at the index level using the desired operative approach
  • 2\. Severe degenerative lesions at more than one level of the lumbosacral spine
  • 3\. Morbid obesity (BMI \= 40\)
  • 4\. Active local infection in or near the operative region
  • 5\. Active systemic infection and/or disease
  • 6\. Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation
  • 7\. Known or suspected sensitivity to the implant materials
  • 8\. Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)
  • 9\. Systemic disease that requires the chronic administration of nonsteroidal anti\-inflammatory or steroidal drugs
  • 10\. Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)

Outcomes

Primary Outcomes

Not specified

Similar Trials